Background:Visceral Leishmaniasis (VL) is a zoonotic disease caused byLeishmaniainfantumin the Mediterranean area. Dogs are the main reservoir ofLeishmaniainf antumparasites. Disease management represents a serious problem, since anti-Leishmaniadrugs have limited efficacy in both symptomatic and asymptomatic dogs, which are infective to phlebotomine vectors. In many tropical and sub-tropical countries the development of a safe and easily-available vaccine has high priority. DNA vaccines represent one of the most recent innovations in the field of immunization.Findings:This study aimed to evaluate the effect of a DNA vaccine based on twoLeishmaniaantigens (Cpb1, PO) in leishmaniotic dogs. Twelve leishmaniotic dogs from a Leishmaniasis-endemic area (Naples, Italy) received three consecutive injections of DNA vaccine at 15-days intervals. Another group of five leishmaniotic dogs received the same amount of pVAX-1 without the coding sequences ofLeishmaniaantigens.LeishmaniaDNA load, INFγ, IL-4 mRNA expression levels and clinical parameters were tested before and after the therapy, every 3 months for a period of 12 months.Analysis of the data in the vaccinated dogs showed: i) a decreaseLeishmaniaDNA load in lymph node samples, ii) an increase of INFγ and IL-4 mRNA expression levels in PBMC samples. All vaccinated dogs also showed an improvement in the clinical symptoms.Conclusion:Our results show that the vaccine developed in this study may represent a useful tool in the treatment of leishmaniotic dogs. However, since the duration of positive effects is limited in time, further trials are needed to evaluate the effectiveness of immunotherapy alone or in association with conventional therapy.

Development and clinical trial of a novel DNA vaccine as immunotherapy during canine Leishmaniasis / Pittau, Marco; Chessa, Bernardo; Manna, Laura; Piras, Ilaria Michela; Della Peruta, Italia; Del Pizzo, Carlo Maria; Coradduzza, Elisabetta; Cacciotto, Carla; Alberti, Alberto; Ciprì, Valentina; Gammarano, Nicoletta; Gravino, Angelo Elio. - 3:6(2012). [10.4172/2157-7560.1000155]

Development and clinical trial of a novel DNA vaccine as immunotherapy during canine Leishmaniasis

Pittau, Marco;Chessa, Bernardo;Piras, Ilaria Michela;Coradduzza, Elisabetta;
2012-01-01

Abstract

Background:Visceral Leishmaniasis (VL) is a zoonotic disease caused byLeishmaniainfantumin the Mediterranean area. Dogs are the main reservoir ofLeishmaniainf antumparasites. Disease management represents a serious problem, since anti-Leishmaniadrugs have limited efficacy in both symptomatic and asymptomatic dogs, which are infective to phlebotomine vectors. In many tropical and sub-tropical countries the development of a safe and easily-available vaccine has high priority. DNA vaccines represent one of the most recent innovations in the field of immunization.Findings:This study aimed to evaluate the effect of a DNA vaccine based on twoLeishmaniaantigens (Cpb1, PO) in leishmaniotic dogs. Twelve leishmaniotic dogs from a Leishmaniasis-endemic area (Naples, Italy) received three consecutive injections of DNA vaccine at 15-days intervals. Another group of five leishmaniotic dogs received the same amount of pVAX-1 without the coding sequences ofLeishmaniaantigens.LeishmaniaDNA load, INFγ, IL-4 mRNA expression levels and clinical parameters were tested before and after the therapy, every 3 months for a period of 12 months.Analysis of the data in the vaccinated dogs showed: i) a decreaseLeishmaniaDNA load in lymph node samples, ii) an increase of INFγ and IL-4 mRNA expression levels in PBMC samples. All vaccinated dogs also showed an improvement in the clinical symptoms.Conclusion:Our results show that the vaccine developed in this study may represent a useful tool in the treatment of leishmaniotic dogs. However, since the duration of positive effects is limited in time, further trials are needed to evaluate the effectiveness of immunotherapy alone or in association with conventional therapy.
2012
Development and clinical trial of a novel DNA vaccine as immunotherapy during canine Leishmaniasis / Pittau, Marco; Chessa, Bernardo; Manna, Laura; Piras, Ilaria Michela; Della Peruta, Italia; Del Pizzo, Carlo Maria; Coradduzza, Elisabetta; Cacciotto, Carla; Alberti, Alberto; Ciprì, Valentina; Gammarano, Nicoletta; Gravino, Angelo Elio. - 3:6(2012). [10.4172/2157-7560.1000155]
File in questo prodotto:
File Dimensione Formato  
Manna_L_Development_and_clinical_trial.pdf

accesso aperto

Tipologia: Versione editoriale (versione finale pubblicata)
Licenza: Creative commons
Dimensione 1.76 MB
Formato Adobe PDF
1.76 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/263836
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact